Access count of this item: 271

Files in This Item:
File Description SizeFormat 
61_5_201.pdf842.27 kBAdobe PDFView/Open
Title: スニチニブ再投与が奏功した転移性腎細胞癌の1例
Other Titles: Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report
Authors: 吉永, 敦史  KAKEN_name
鎌田, 成芳  KAKEN_name
Author's alias: Yoshinaga, Atsushi
Kamata, Shigeyoshi
Keywords: Metastatic renal cell carcinoma
Sunitinibrechallenge
Axtinib
Issue Date: May-2015
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要 = Acta urologica Japonica
Volume: 61
Issue: 5
Start page: 201
End page: 205
Abstract: A 67-year-old woman underwent radical nephrectomy (clear cell carcinoma, G2>3, pT2b) for left renal cancer with pulmonary metastasis. After interferon-α treatment for 7 months, right iliac bone metastasis occurred. Pulmonary and right ileac bone metastases became larger after 4 months of first sunitinib administration. Replacement by everolimus treatment was not effective. After 6 months of sunitinib rechallenge therapy, pulmonary metastasis disappeared and right ileac bone metastasis became smaller. However, 1 month later, right costal and left femoral metastases occurred. She was kept on sunitinib treatment, and there were no changes in these metastases for 1 year. However, it was difficult to continue sunitinibtreatment because of side effects, resulting in growth of metastases. Costal and femoral metastases showed a partial response to axtinibtreatment given thereafter. Tyrosine kinase inhibitor rechallenge therapy had potential benefits and was tolerated in selected metastatic renal cell carcinoma patients.
Rights: 許諾条件により本文は2016/06/01に公開
URI: http://hdl.handle.net/2433/198516
PubMed ID: 26087822
Appears in Collections:Vol. 61 No. 5

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.